CIDP - Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barré Syndrome (GBS)
Conditions
Keywords
MSOT, PAI, Nerve Ultrasound
Brief summary
The aim of this study is to assess disease activity in patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Guillain-Barré Syndrome (GBS) using multispectral optoacoustic tomography (MSOT). The currently available diagnostic procedures for CIDP and GBS do not allow for a clear distinction between remission and active disease and show limitations in sensitivity and specificity during acute diagnostics. This can lead to delayed diagnosis, which is crucial for timely initiation of therapy and, consequently, for a better prognosis. Long-term therapy management is also challenging, as objective parameters for assessing therapeutic success are largely lacking. MSOT can detect inflammation through the measurement of hemoglobin, a method that our research group has already successfully demonstrated in patients with chronic inflammatory bowel diseases (Knieling, NEJM 2017). The use of MSOT could therefore also be applied to nerve inflammation, allowing for earlier detection of inflammation and nerve damage and contributing to timely treatment of patients. For nerve imaging, a CE-certified MSOT device from iThera Medical is available at the Pediatric Clinic in Erlangen. In addition, a non-CE-certified device with lower laser power is available, which can be used for bedside examinations. The arm nerves will be examined in three cohorts, which will be compared with each other and with standard diagnostics (blood tests, electrophysiology, conventional ultrasound). Each cohort will include ten healthy control subjects, ten patients with CIDP, and ten patients with GBS.
Interventions
None listed
Sponsors
University of Erlangen-Nürnberg Medical School
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
Patient Cohort(s): * Established diagnosis or suspected CIDP or GBS * Age: 18 years or older * Written informed consent provided by participant Inclusion Criteria Control Cohort: * Written informed consent provided by participant * Age: 18 years or older * No pre-existing conditions that may affect peripheral nerves (e.g., diabetes, traumatic nerve injuries, etc.)
Exclusion criteria
* Pregnancy * Breastfeeding mothers * Cardiopulmonary instability * Tattoo in the examination area * Subcutaneous fat tissue \> 3 cm
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Single Wavelength PA signal | Single time point | Photoacoustic single wavelength signal between 700nm and 1100nm in the measured nerves. |
| PA hemoglobin signal | Single time point | Unmixed photoacoustic hemoglobin signal (oxygenated, deoxygenated and derived saturation) in the measured nerves |
| Doppler signal | Single time point | Ultrasound-based Doppler signal in the measured nerves |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| PA water signal | Single time point | Unmixed photoacoustic water signal in the measured nerves |
| Nerve diameter | Single time point | Ultrasound-based dimensional measurements of the respective nerve. |
| PA collagen signal | Single time point | Unmixed photoacoustic collagen signal in the measured nerves |
| Clinical scores | Single time point | Assessment of clinical scores (MRC, NIS) for correlation with imaging data. |
| PA lipid signal | Single time point | Unmixed photoacoustic lipid signal in the measured nerves |
Contacts
Primary ContactFelix Wachter, Dr. med.
Backup ContactAdrian Bühler, M.Sc.
Outcome results
None listed